Drug intelligence / Profile preview

SAF-1 antisense shRNA

Development stage
Preclinical
Lead developer
University of Missouri
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous, Parenteral
01

Overview

SAF-1 antisense shRNA is a short hairpin RNA (shRNA) designed to target and silence the expression of Serum Amyloid A-Activating Factor-1 (SAF-1), also known as Myc-Associated Zinc Finger Protein (MAZ). Developed primarily as a research tool by researchers at the University of Missouri, this RNA interference (RNAi) agent is used to investigate the role of the SAF-1 transcription factor in chronic inflammation, angiogenesis, and cancer progression. In preclinical breast cancer models, knockdown of SAF-1 using this shRNA significantly downregulates the expression of vascular endothelial growth factor (VEGF) and Ras (H-Ras and K-Ras), leading to the inhibition of tumor-induced angiogenesis, endothelial cell proliferation, and tumor growth.

Other names
MAZ shRNAMAZ short hairpin RNASAF-1 shRNASAF1 shRNASAF 1 shRNASAF-1-specific short hairpin RNASAF1-specific short hairpin RNASAF 1-specific short hairpin RNA
02

Targets

Beyond the preview

Go deeper on SAF-1 antisense shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SAF-1 antisense shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call